Page 147 - CW E-Magazine (29-10-2024)

Top Stories Pharmaceuticals

ENSURING FAIR TRADE PHARMA EXHIBITION

Govt. not to enter into negotiations on fresh FTAs CPHI & PMEC India Expo to be held from Nov 26-28

as it revisits strategy in Greater Noida

The Government has pressed the Negotiations are temporarily on in our talks with, for instance, Oman,” Leading events organiser, Informa expanding its global reach and engage-
pause button on all fresh free trade hold even for the FTAs where talks the source said. Markets, has announced that the 17th ment.
agreements (FTAs) as it is revisiting have been initiated but are not at an ad- edition of the pharma industry trade
its negotiating strategy in order to have vanced stage, like Peru and Chile, but The SOPs also talk about being event, CPHI & PMEC India Expo, will The event will also feature dedi-
more “meticulously” planned pacts, could continue if approval comes from more meticulous while giving conces- take place from November 26-28, 2024, cated spaces like the Customer Insights
according to a report in the Hindu Busi- the top. However, with partners such sions taking into account not only the at the India Expo Centre, Greater Noida. Lounge, International Lounge, B2B
nessLine newspaper. as the UK and the EU, where talks have present but future possibilities and Lounge, Sustainability Lounge, Con-
progressed considerably, negotiations risks. Similarly, the risk of third country According to Informa, the event ference Hall, and a Sales Offi ce. Start-
The idea is to avoid giving unin- continue. items, especially Chinese products, will bring together over 50,000 industry ups will have exclusive opportunities
tended concessions, check third coun- coming into India at concessional professionals and 2,000 exhibitors show- ness growth, and spearheading new to accelerate their growth by tapping
try goods (mostly from China) coming In the last fi ve years, India’s total duties routed through partner countries casing more than 10,000 innovative pro- initiatives,” commented Mr. Yogesh into funding avenues, mentorship pro-
in from partner countries, help industry imports from FTA partners (ASEAN, need to be more seriously addressed. ducts across the pharmaceutical value Mudras, Managing Director of Informa grammes, and expansive industry net-
gain more market access, reject strin- UAE, SAFTA, Australia, South Korea, chain. CPHI will focus on key segments Markets in India. works through the ‘Start Up Market’,
gent sustainability rules and be more Japan and Mauritius) increased by The SOPs also highlight the need such as natural extracts, pharma exci- designed to foster innovation and
balanced in terms of give and take, 37.9% to $187.92-bn while its exports to avoid non-tariff barriers such as pients, fi nished dosage formulations, Notable exhibitors at CPHI this year collaboration. In addition to the main
the report quoted unnamed sources as increased by 14.48% to $122.72-bn, sustainability issues, including labour pharma ingredients, and fi ne chemicals, include Dr. Reddy’s, Biocon, Glenmark exhibition, CPHI & PMEC India will
saying. per an analysis done by research body, standards and environmental norms, while PMEC will highlight pharma- Lifesciences, Morepen Laboratories, host several initiatives during the ‘India
Global Trade Research Initiative. While that are pushed by developed nations, ceutical machinery, packaging and drug Hetero Labs, and Merck Lifesciences, Pharma Week’, including the ‘Pharma
“The SOPs (standard operating some part of the trade was not using and a more balanced approach while delivery systems, clean technology, while PMEC will feature names like Leaders Roundtable’, ‘Women in
procedures) for the new FTA strategy FTA concessions, the ASEAN coun- dealing with smaller nations, such as environmental protection, laboratory, ACG, Fette, Snowbell, Toffl on, Jicon, Pharma Conference’, ‘Pharma Connect
are ready and a Cabinet note is being tries, the UAE, Japan and the SAFTA Sri Lanka or Bangladesh, to ensure that analytical, and biotech equipment. and Pacifab. This year’s edition is set Congress’ besides the 10th edition of
prepared by the Commerce Depart- nations appear to have gained dispro- India gains proportionately. to attract participation from over 120 the ‘India Pharma Awards’ recogni-
ment. Past FTAs, including recent ones portionately. “As India and South Asia lead global countries. The event is endorsed by sing outstanding contributions to the
with the UAE and Australia, have been The Commerce Department had pharmaceutical innovation, this expo prominent industry associations and pharmaceutical industry. This year, the
minutely studied to understand where The idea behind the new strategy organised a ‘chintan shivir’ on FTA will continue to be the ideal platform will also feature the Pharmaceutical CPHI legacy brand is celebrating its
things could have been done better and is to learn from past experiences. “For strategy and SOPs for trade nego- for fostering connections, driving busi- Supply Chain Initiative (PSCI), further 35th anniversary.
where things went wrong. New FTAs instance, after our experience with the tiations in May this year where brain
are likely to be negotiated once the UAE, where there are problems related storming sessions were held between INDIGENOUS EFFORT
SOPs are in place,” the report quoted to imports of gold, silver, platinum and offi cials and trade experts including Wockhardt seeks DCGI approval for its version
an offi cial as saying. dates, we don’t want to repeat the same past negotiators.

QUARTERLY RESULTS of Aspart insulin
Aether Industries achieves 10.43% growth in sales
Wockhardt has approached the second largest number of people with “By leveraging integrated infra-
Aether Industries Ltd., a leading working capital cycle, paving a way tracker solar power plant, which is Drug Controller General of India diabetes in the world. Last year, structure and expertise, Wockhardt has
specialty chemical manufacturer, has to better ratios in near future and has expected to signifi cantly reduce electri- (DCGI) seeking approvals for its indi- USV said it had partnered with bio- completed all stages of Asparapid deve-
reported revenue from Sales at Rs. registered a positive cash fl ow from city costs. “The plant’s innovative auto- genously developed, fast-acting insulin tech venture Biogenomics to bring out lopment – from research to production
198.80-crore in Q2 FY25, a 10.43% operations for both the quarter and the tracking system will maximise energy analogue, Aspart injection (Asparapid). ‘InsuQuick’, the fi rst locally-made bio- through in-house development,” the
increase compared to Q1 FY25. EBITDA six-month period under review, under- effi ciency, leading to better tax savings similar version of Insulin Aspart. company said. Further, it pointed out
for Q2 FY25 was Rs. 61.28-crore, up scoring its commitment to effi cient through depreciation benefi ts, while Insulin Aspart is a rapid-acting that, “Asparapid will be available in
17.56% from the previous quarter, fi nancial management and operational also boosting cash fl ows. With the product originally from multinational Wockhardt is also developing addi- cartridges, vials, and prefi lled disposable
while Profi t After Tax (PAT) increased excellence,” it said in a statement. fi nal phase of this project set to go Novo Nordisk and is sold globally as tional insulin analogues and GLP-1 pens, offering fl exibility to the patients for
to Rs. 34.80-crore in Q2 FY25, regis- live within a month, we will soon start ‘NovoLog’ or ‘NovoRapid’. However, agonists as part of its comprehensive management of diabetes.” The market
tering a 16.26% rise. “Additionally, the The company also announced the generating additional revenue for the locally developed products are gaining strategy to provide advanced diabetes for Aspart in India is estimated at
company has successfully reduced its commencement of its new 5-MW auto company,” the statement added. in signifi cance, since India has the care solutions, the company said. Rs. 260-crore, with limited participants.

146 Chemical Weekly October 29, 2024 Chemical Weekly October 29, 2024 147

Contents Index to Advertisers Index to Products Advertised